---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-094788"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:28:55.277329+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences Q2 net loss $8.4M; cash $12.1M, plans Phase 1b

## Summary
- Net loss for Q2 2024 of $8.4M ($5.13 per share) vs $1.4M loss in Q2 2023.
- Net loss for H1 2024 of $11.1M ($8.13 per share) vs net income of $4.7M in H1 2023.
- Cash and equivalents $12.1M as of June 30, 2024, up from $12.0M at Dec 31, 2023.
- Completed Phase 1 dosing of Gemini; safety endpoint met with biomarker activity.
- Phase 1b study in CKD patients expected to start in H2 2024.

## SEC filing metadata
- accession: 0000950170-24-094788
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017024094788/0000950170-24-094788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017024094788/revb-20240809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-094788
- JSON: https://secwatch.observer/filing/0000950170-24-094788.json
- Plain text: https://secwatch.observer/filing/0000950170-24-094788.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.